血清PTX3表达与非小细胞肺癌骨转移的相关性分析  

Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer

作　　者：李多 郝昭昭 陈延伟 南岩东 Li Duo;Hao Zhaozhao;Chen Yanwei;Nan Yandong(Department of Respiratory and Critical Care Medicine,Tangdu Hospital,Air Force Military Medical University,Xi′an,710038,China)

机构地区：[1]空军军医大学唐都医院呼吸与危重症医学科,西安710038

出　　处：《中华肺部疾病杂志（电子版）》2024年第4期558-562,共5页Chinese Journal of Lung Diseases(Electronic Edition)

基　　金：唐都医院高层次人才启动项目(2021YFJH0011)。

摘　　要：目的分析血清正五聚蛋白3(pentraxin 3,PTX3)表达与非小细胞肺癌(non-small cell lung cancer,NSCLC)骨转移的相关性及临床意义。方法选取2022年9月至2023年7月我院收治的184例转移性NSCLC患者,NSCLC骨转移69例为观察组,NSCLC非骨转移115例为对照组。收集患者临床资料,采用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测血清PTX3表达水平。对比两组血清PTX3含量,分析血清PTX3表达与NSCLC骨转移的相关性,比较治疗前后NSCLC骨转移血清PTX3表达。采用受试者工作特征曲线(receiver operating characteristic,ROC)判断血清PTX3对NSCLC骨转移诊断。结果两组性别、年龄差异无统计学意义(P>0.05)。观察组骨转移69例,对照组淋巴结转移40例、肺转移31例、脑转移21例、肝转移14例、肾上腺转移12例。观察组血清PTX3104.80(175.48)ng/ml高于对照组21.48(22.02)ng/ml(P<0.05)。血清PTX3表达与NSCLC骨转移者性别、年龄、癌症史、吸烟指数、BMI指数、病理类型、原发灶位置、单器官转移、转移灶数量、骨转移性质、血钙、血碱性磷酸酶差异无统计学意义(P>0.05)。治疗前后NSCLC骨转移血清PTX3表达差异无统计学意义(P>0.05)。血清PTX3诊断NSCLC骨转移的ROC曲线下面积为0.860(95%CI:0.802~0.919),最佳诊断截断值为35.385 ng/ml,灵敏度和特异度分别为0.855和0.748。结论血清PTX3高表达与NSCLC骨转移密切相关,对NSCLC骨转移诊断具有临床意义。Objective To analyze the correlation and clinical significance of serum pentraxin 3(PTX3)expression with bone metastasis of non-small cell lung cancer(NSCLC).Methods A total of 184 metastatic NSCLC patients treated in Tangdu Hospital from September 2022 to July 2023 were selected.69 cases of NSCLC bone metastasis were the observation group,and 115 cases of NSCLC non-bone metastasis were the control group.The clinical information of patients was collected,and the expression level of serum PTX3 was detected by enzyme-linked immunosorbent assay(ELISA).Compared serum PTX3 content of two groups,we analyze the correlation of PTX3 expression with NSCLC bone metastases and compared serum PTX3 expression in NSCLC bone metastases before and after treatment.Receiver operating characteristic(ROC)curve was used to determine the diagnostic value of serum PTX3 for NSCLC bone metastasis.Results There were no significant differences in gender and age between the two groups(P>0.05).There were 69 cases of bone metastasis in the observation group and 40 cases of lymph node metastasis,31 cases of lung metastasis,21 cases of brain metastasis,14 cases of liver metastasis and 12 cases of adrenal metastasis in the control group.The serum PTX3 in the observation group was 104.80(175.48)ng/ml,which was higher than that in the control group 21.48(22.02)ng/ml(P<0.05).There were no significant differences of serum PTX3 expression in NSCLC bone metastasis patients with different clinical characteristics,including gender,age,history of cancer,smoking index,BMI index,pathological type,primary tumor location,single organ metastasis,number of metastatic lesions,nature of bone metastasis,blood calcium and serum alkaline phosphatase(P>0.05).There was no significant difference in the expression of serum PTX3 in NSCLC patients with bone metastasis before and after clinical treatment(P>0.05).The area under ROC curve of serum PTX3 in the diagnosis of NSCLC with bone metastasis was 0.860(95%CI:0.802~0.919),with the optimal diagnostic cut-off value,sensit

关 键 词：非小细胞肺癌 正五聚蛋白3 骨转移 相关性分析 

分 类 号：R734.2[医药卫生—肿瘤]